Eikon Therapeutics, a biotechnology company focused on integrating engineering and molecular biology for drug discovery, has secured $350.7 million in Series D financing. This latest funding round brings the company’s total private investment to over $1.1 billion since its founding in 2019. The financing was led by existing investors, with participation from new investors, including mutual funds, sovereign wealth funds, and healthcare-focused venture firms including Lux Capital, The Column Group, and General Catalyst. CEO Roger M. Perlmutter said that the funding will support the expansion of Eikon’s research and development capabilities and further the company’s mission of delivering innovative treatments for serious illnesses.
Josh Wolfe, Lux Capital’s Co-founder and Managing Partner, said, “By harnessing its proprietary single molecule tracking technology, Eikon is uncovering biological processes in living cells with an unprecedented level of precision, generating insights at a pace that was previously out of reach. With a skilled leadership team that is deeply experienced in bringing groundbreaking therapies to patients, Eikon is setting a new standard for innovation in biotechnology.” The company is also advancing EIK1003, a selective PARP1 inhibitor in early-stage trials for multiple cancers, and EIK1004, a central nervous system-penetrant PARP1-selective inhibitor targeting brain cancers. In addition, its early-stage pipeline includes androgen receptor antagonists and EIK1005, a WRN inhibitor for MSI-high and DNA repair–deficient cancers.
